IL7R and hematopoietic and lymphoid cell neoplasm: The inhibition of IL-7R signaling has been investigated across various malignancies, particularly hematologic cancers such as T-cell and B-cell acute lymphoblastic leukemia, and multiple therapeutic strategies are under development [40,41,42,43,44].